title: Clinical study of high-flux cuprammonium rayon hemodialysis membranes.
abstract: The aim of this crossover clinical study was to gain basic information on the hemocompatibility and effectiveness of recently developed high-flux membranes made of cuprammonium rayon with ultrafiltration coefficients of 10, 17, and 19 ml/mm Hg/h (S12W, SU12W, and SS12W dialyzers, respectively), and to identify any possible differences from a conventional membrane made of the same material with an ultrafiltration coefficient of 6 ml/mm Hg/h (C12W dialyzer). All the tested membranes led to an abrupt drop in leukocyte count in the initial phase of hemodialysis. In high-flux membranes, C5a anaphylatoxin would pass into the dialysate, but mean C5a anaphylatoxin concentrations in the dialysate were lower by orders of magnitude than its plasma concentrations, which behaved, in high- and low-flux membranes alike, typically of those made of nonsubstituted cellulose with no intermembrane differences. As judged by the concentrations of the thrombin-antithrombin III complex, the coagulation system was activated--again, without differences between membranes. The reduction rates for urea, creatinine, and phosphates were comparable for all the tested membranes. Compared with baseline, the post-dialysis serum concentrations of beta 2-microglobulin in high-flux membranes, unlike the low-flux membrane, were significantly lower. We conclude that there are no significant differences between the tested high- and low-flux membranes made of cuprammonium rayon in the monitored hemocompatibility parameters, and that high-flux membranes are capable of reducing serum beta 2-microglobulin concentrations.
authors.affiliation: Department of Medicine, Strahov Hospital, Prague, Czech Republic.
authors.forename: K
authors.initials: K
authors.lastname: Opatrný
authors.forename: S
authors.initials: S
authors.lastname: Sulková
authors.forename: F
authors.initials: F
authors.lastname: Lopot
authors.forename: L
authors.initials: L
authors.lastname: Vít
authors.forename: A
authors.initials: A
authors.lastname: Válek
authors.forename: K
authors.initials: K
authors.lastname: Opatrný
mesh_terms: D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000032:analysis; D002482:Cellulose / Q000031:analogs & derivatives*; D015936:Complement C5a / Q000032:analysis; D015312:Hemodialysis Solutions / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D007958:Leukocyte Count; D008567:Membranes, Artificial; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D006435:Renal Dialysis / Q000295:instrumentation*; D001613:beta 2-Microglobulin / Q000032:analysis
chemical_list: D015312:Hemodialysis Solutions; D008567:Membranes, Artificial; C046193:antithrombin III-protease complex; D001613:beta 2-Microglobulin; C066013:AM 160H; D015936:Complement C5a; D000990:Antithrombin III; D002482:Cellulose; D010447:Peptide Hydrolases